---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-015079"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:39:33.381071+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics appoints Yu Ding as CFO, Qinglai Lu to board; CFO Nir Sassi resigns

## Summary
- Nir Sassi resigned as CFO effective April 1, 2026; resignation not due to disagreement.
- Yu Ding appointed CFO effective April 1, 2026; brings experience from Grand Auto Service and Hong Kong listed firms.
- Qinglai Lu appointed to Board of Directors effective April 8, 2026; deemed independent.
- Qinglai Lu also appointed to Audit Committee along with Jerome Jabbour; Matthew McMurdo resigned from Audit Committee.
- New CFO Yu Ding has over 20 years experience in financial planning, capital management.

## SEC filing metadata
- accession: 0001493152-26-015079
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315226015079/0001493152-26-015079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315226015079/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-015079
- JSON: https://secwatch.observer/filing/0001493152-26-015079.json
- Plain text: https://secwatch.observer/filing/0001493152-26-015079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.